PHASE 2 STUDY OF PARSACLISIB (INCB050465) FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (CITADEL‐202). (12th June 2019) - Belada, D.; Fay, K.; Casasnovas, R.; Gressin, R.; Lee, H.; Mehta, A.; Munoz, J.; Verhoef, G.; Corrado, C.; DeMarini, D.; Zhao, W.; Chen, X.; et al.